Elephant On Dark Background.jpg

WHERE EVOLUTIONARY MEETS REVOLUTIONARY TO IMPROVE HUMAN HEALTH

Who We Are

Nature continuously pushes the limits of biology, yet these phenomenal outcomes rarely make their way to patients. At Peel Therapeutics, we are determined to change that.  

We are an evolutionary-inspired, clinical-stage biotech company developing medicines to transform patients’ lives. Peel (the Hebrew word for “elephant”) launched with a focus on cancer-fighting proteins in elephants and quickly recognized the power of using evolution's solutions to treat and prevent disease. In addition to developing elephant p53 (EP53) nanoparticles for the treatment of cancer, our team is advancing additional therapies derived from nature’s super-abilities to treat a number of diseases.  

Asset Tree without descriptions.PNG
 

Our Approach

Life science R&D has produced countless new therapies with positive health outcomes, but it cannot compare to ages of evolutionary history. We seek out distinct proteins and molecules in nature that have exceeded what we thought was biologically possible. We then apply our expertise and technology to rapidly translate this evolutionary biology and advance our therapeutic pipeline to treat a spectrum of devastating conditions, including cancer and inflammation.  

 

Our Leadership

Our multidisciplinary team across the US and Israel offers a unique blend of scientific and medical expertise, enthusiasm and curiosity. We hail from all corners of academia and clinical medicine, and the patients we serve are the driving force behind the work we do every day.    

LEADERSHIP TEAM

(Peel)_Joshua Schiffman_Picture.jpg

Joshua Schiffman, MD

Co-Founder &

Chief Executive Officer

(Peel)_Jim Levison_Picture.jpg

James Levison, MBA
Chief Financial Officer

9X4A3476.jpg

Debra Vallner, PhD, MBA
Sr. VP, Development
Operations

MorG_pic1.jpg

Mor Goldfeder, PhD
VP, Technology &
Early Development,
Managing Director
of Peel Israel 

(Peel)_Aleah Caulin_Picture (first choice) (1).jpg

Aleah Caulin, PhD
VP, Nonclinical

(Peel)_Trent Fowler_Picture.jpg

Trent Fowler, MBA
VP, Operations

Adi Profile.jpg

Adi Dror, PhD
Director of Protein Development

Nitzan3.jpg

Nitzan Krinsky, PhD
Director of Formulation & Assay Development 

 
 

BOARD OF DIRECTORS

John%20Warnock_edited.jpg

John Warnock, PhD

Mary Tolan, MBA

Willard Dere, MD

(Peel)_Joshua Schiffman_Picture.jpg

Joshua Schiffman, MD
CEO | Co-Founder

Avi Schroeder, PhD
Co-Founder

 

BOARD OF ADVISORS

(Advisors)_Sam Blackman_Picture.jpg

Sam Blackman, MD, PhD

(Advisors)_Mark Blumenkranz_Picture.jpeg

Mark Blumenkranz, MD, MMS

(Advisors)_Matt LaMarche_Photo.jpg

Matt LaMarche, PhD

Cutler.png

Adam Cutler

Sullivan.png

Jay Sullivan, JD

(Advisors)_Yosef Zweibach_Picture.png

Yosef Zweibach